Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes reviewing medical history and current health status.

The assessment ensures that the participant has moderately to severely active Crohn’s disease, confirmed by specific scores from medical evaluations.

Participants are randomly assigned to receive either the active medication, MORF-057, or a placebo. The study is double-blind, meaning neither the participant nor the study team knows which treatment is being administered.

The medication is provided in capsule form for oral use.

Participants take the assigned capsule daily. The dosage and specific regimen are determined by the study protocol.

The treatment period lasts for 14 weeks, during which the participant’s response to the medication is closely monitored.

Regular assessments are conducted to monitor the participant’s health and response to the treatment. This includes checking for any side effects and evaluating the effectiveness of the medication.

Endoscopic evaluations are performed to assess the condition of the intestines at the end of the 14-week period.

At the end of the treatment period, a final evaluation is conducted to determine the participant’s response to the treatment.

The primary goal is to assess the proportion of participants who show an endoscopic response, indicating improvement in the condition.